Fig. 9From: First-line nivolumab plus ipilimumab for unresectable MPM in China: a cost-effectiveness analysisThe cost-effectiveness acceptability curves of patients with epithelioid histology. CE Cost-effectiveness, E Patients with epithelioid histology, NI Nivolumab plus ipilimumab, C Pemetrexed plus cisplatin/carboplatinBack to article page